Alamar Lunch & Learn at University of Alabama at Birmingham

January 22, 2026
Birmingham, AL, USA
Topic:
Booth:

Summary

Tinsley Harrison Tower
Rm 740
1900 University Blvd
Birmingham, AL 35294

*Lunch will be provided

 

Unlocking the Power of Fluid Biomarkers

Join Alamar Biosciences for a Lunch & Learn seminar at University of Alabama at Birmingham to discover how the NULISA™ Platform and ARGO™ HT System are transforming research in CNS diseases and beyond. This seminar will offer an open discussion on how Alamar’s tools can support and accelerate your work.

The NULISA™ Platform delivers ultra-high sensitivity, broad dynamic range, and high multiplexing capabilities for precise biomarker detection and quantitation. Paired with the ARGO™ HT System—a fully automated, high-throughput platform capable of generating single-plex results in under 8 hours and multiplex results in under 15 hours—researchers can achieve faster, more reliable data with minimal hands-on time.

Don’t miss this opportunity to engage with experts from Alamar Biosciences for a lively discussion on the cutting-edge capabilities of NULISA and the ARGO HT System.

Agenda

11:45-12:00 pm
CHECK IN & LUNCH
12:00-12:45 pm
INTRODUCTION + CASE STUDY
  • Alamar Bio & NULISA Technology
  • Ultrasensitive Biomarker Detection for Neurogenerative Disease, Oncology and Beyond with NULISA

12:45-1:00 pm

Q&A

Presenter

  • Berendia Jackson
    Executive Business Partner
    Alamar Biosciences

Sign Up to Attend

This event is currently closed for registrations.

Seminar Registration-Lunch&Learn-UAB
Name
Name
First
Last

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.